All In MedTech

Device Trial Radar · NCT06891898

The iLet Experience Study

iLet Dosing Decision Software Postmarket Surveillance Plan (PS240001): The iLet Experience Study

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,875

Planned (sponsor's estimate)

Start

May 1, 2024

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Beta Bionics, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
The Scripps Research Institute
First posted
Mar 24, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.

Conditions

  • Type 1 Diabetes

Interventions

  • iLet Dosing Decision SoftwareDevice

    Interoperable alternate glycemic controller

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severe Hypoglycemia/cognitive impairmentTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beta Bionics

    Irvine, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.